Randomized, Double-Blind, Placebo Controlled Phase II Study of FOLFOX +/- Ziv-Aflibercept in Patients With Advanced Esophageal and Gastric Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Gastric cancer; Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 09 May 2016 Status changed from recruiting to active, no longer recruiting.
- 09 May 2016 Planned primary completion date changed from 1 Feb 2015 to 1 Sep 2016.